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Abstract: Background:  MicroRNAs (miRNA) regulate the translation of mRNA during gene
expression and investigations have highlighted their importance in pathophysiology.
qRT-PCR is currently the gold standard method for detecting changes in miRNA
expression. However, when used on heterogeneous samples, it cannot identify
individual cell types harbouring miRNAs. For this,  in situ  hybridisation (ISH) can be
used. ISH methods using locked nucleic acid (LNA) probes have been shown to give
reliable results in formalin fixed paraffin embedded (FFPE) samples. In this study their
use has been directly compared with conventional oligonucleotide probes (COP) for
ISH.
Methods:   FFPE samples of colorectal adenocarcinoma, squamous carcinoma of lung
and cases of invasive breast carcinoma were used to evaluate COP and LNA methods
for the demonstration of miR-126 and miR-205. To demonstrate the utility of the COP
method demonstration of miR-21 in 19 Gleason stage 7 prostate biopsy FFPE tissues
was also undertaken. The demonstration of miR-21 by ISH in high and low expressing
prostate cancer cell lines was also compared with qRT-PCR.
Results:  Similar results were obtained using the COP and LNA ISH methods for the
demonstration of miR-126 and miR-205. miR-21 was successfully demonstrated in the
prostate cancer samples by COP ISH and expression levels of the miRNA
demonstrated in the cell lines corresponded with qRT-PCR.
Conclusion:  This study has shown that simplification of ISH protocols by the use of
COPs provides equivalent results to the use of LNA methods and it can be used to
precisely identify cells in which miRNA are expressed.
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Background: MicroRNAs (miRNA) regulate the translation of mRNA during gene expression 
and investigations have highlighted their importance in pathophysiology. qRT-PCR is 
currently the gold standard method for detecting changes in miRNA expression. However, 
when used on heterogeneous samples, it cannot identify individual cell types harbouring 
miRNAs. For this, in situ hybridisation (ISH) can be used. ISH methods using locked nucleic 
acid (LNA) probes have been shown to give reliable results in formalin fixed paraffin 
embedded (FFPE) samples. In this study their use has been directly compared with 
conventional oligonucleotide probes (COP) for ISH.  
Methods: FFPE samples of colorectal adenocarcinoma, squamous carcinoma of lung and 
cases of invasive breast carcinoma were used to evaluate COP and LNA methods for the 
demonstration of miR-126 and miR-205. To demonstrate the utility of the COP method 
demonstration of miR-21 in 19 Gleason stage 7 prostate biopsy FFPE tissues was also 
undertaken. The demonstration of miR-21 by ISH in high and low expressing prostate cancer 
cell lines was also compared with qRT-PCR. 
Results: Similar results were obtained using the COP and LNA ISH methods for the 
demonstration of miR-126 and miR-205. miR-21 was successfully demonstrated in the 
prostate cancer samples by COP ISH and expression levels of the miRNA demonstrated in 
the cell lines corresponded with qRT-PCR. 
Conclusion: This study has shown that simplification of ISH protocols by the use of COPs 
provides equivalent results to the use of LNA methods and it can be used to precisely 





































































MicroRNAs (miRNA) represent a non-coding family of 21-25 nucleotide long RNAs that 
regulate translation during gene expression [1,2]. A single miRNA can target hundreds of 
individual mRNAs and they have been shown to play an important role in pathophysiology 
[3,4]. They regulate cell proliferation, apoptosis, cell differentiation, cell migration and cell 
cycle control; processes that are linked to cancer [5,6]. 
The expression levels of miRNAs have been extensively studied using molecular methods 
such as qRT-PCR on homogenate sample preparations. These methods provide for the rapid 
and quantitative assessment of miRNAs and determination of their altered expression in 
pathological states. Applied to homogenous cell populations they provide a reliable 
indicator of alteration of miRNA expression. However, in situations where the cell 
population is heterogenous, as in tissue samples, then they provide only an overall indicator 
of expression, but cannot identify the alteration of miRNA levels in individual cell types. The 
latter has been shown to be important in the clarifying potential conclusions for the role of 
individual miRNAs in disease. In particular, the assignment of miR-143 and miR-145 as 
inhibitors of tumourigenesis in colonic cancer was shown, at the cellular level, to be 
associated with changes in mesenchymal derived smooth muscle and myofibroblast cells 
involved in repair processes instead [7]. In this study in situ hybridisation (ISH) was used to 
clarify the alterations in miRNA expression at the cellular level. In a commentary on this 
work Kent, et al [8] strongly advocated that ISH should always be used alongside techniques 
that provide an overall indication of miRNA expression in order to assist in arriving at an 




































































miRNAs have been successfully demonstrated by ISH using locked nucleic acid probes 
(LNA) applied to formalin fixed paraffin embedded (FFPE) tissue sections [9]. It has been 
proposed that due to their high hybridisation efficiency that this type of probe is required to 
ensure optimal hybridisation to the short miRNA sequences. 
With the purpose of providing an alternative ISH method, conventional oligonucleotide 
probes (COP) were used to demonstrate miR-126 and miR-205 in FFPE sections of colorectal 
carcinoma (CRC), squamous carcinoma (SCC) of lung and cases of invasive breast carcinoma 
(IBC). When compared with the use of LNA probes of identical sequence similar results 
were obtained. To further explore the use of COP ISH miR-21 was assessed in 19 Gleason 
stage 7 prostate core biopsy FFPE tissues. COP ISH and qRT-PCR was also undertaken on 
high and low expressing prostate cancer cell lines with a positive consensus in results being 
demonstrated. 
Materials and methods 
FFPE sections of CRC from surgical resections and core biopsy SCC of lung were obtained 
from Queen’s London Hospital, London. FFPE sections from 20 Gleason stage 7 prostate 
core biopsies were obtained from the University College London Cancer Institute, Biobank 
and Pathology Core Facility Service, London.  All were transferred and held in the University 
of Westminster Biobank in compliance with Human Tissue Authority regulations. FFPE IBC 
blocks held in the University of Westminster, Against Breast Cancer Tissue bank were also 
used. Sections from these surgical resection cases were cut at 4 µm.  All sections were 




































































Prostate cancer cell lines, LNCaP and PC3 were obtained from the American Type Culture 
Collection (Manassas, USA). These were maintained in Roswell Park Memorial Institute 
(RPMI) 1640 (Gibco-Life Technologies, UK) with 10% (v/v) heat-inactivated foetal bovine 
serum (Pan Biotech, Germany) and penicillin-streptomycin (10,000 units penicillin / ml, 10 
mg streptomycin / ml - Pan Biotech, Germany) at 37 qC in a humidified 5 % CO2 incubator. 
For the preparation of FFPE cell blocks for ISH harvested cells were collected into 
phosphate-buffered saline (PBS) and centrifuged for 5 mins at 2700 g twice and the pellets 
re-suspended in 100 µl of PBS. 10 ml of neutral buffered formalin (NBF) was added and the 
cells were fixed for 30 mins. The cells were then washed and centrifuged twice in PBS as 
before. 10% gelatine dissolved in tris buffered saline was prepared and 0.5 ml added to the 
cell pellets. After hardening, each cell block was re-fixed in NFB for 30 mins. Following 
washing in PBS, the blocks were held overnight in 70 % alcohol at 4 °C. They were then 
immersed in 100 % alcohol at ambient temperature for 45 mins then in the same for 60 
mins, two changes of xylene for 45 mins each, immersed in paraffin wax and then 
embedded in the same. Sections from the cell blocks were cut at 5 μm and mounted on 
SuperFrost plus slides. 
A ready to use fluorescein labelled Poly d (T) probe (Leica, POLYDT, UK) was used to assess 
the overall preservation of RNA in each sample and to determine the optimal Proteinase K 
concentration required to unmask miRNA. 
The COPs for demonstration of specific miRNA species were obtained from Integrated DNA 
Technologies, BVBA, Belgium. The sequences for miR-21, miR-126, miR-205 and scrambled 




































































probes were labelled with digoxigenin (DIG) inserted as an NHS ester 3’ and 5’ during 
synthesis and HPLC purified before delivery. The DIG labelled oligonucleotides were 
reconstituted in 1 x TE pH 8.0 aliquoted and stored at -20 qC until used.  
For comparative purposes LNA Digoxigenin labelled miR-126 probe together with pre-
treatment and detection reagents (90005) and LNA Digoxigenin labelled miR-205 probe, 
(18099-15) were obtained from Exiqon, Denmark. 
All cases for in situ hybridisation were initially screened for the presence of mRNA and 
determination of optimal Proteinase K pre-treatment using the poly d (T) probe. 
Subsequently samples were hybridised with the Digoxigenin labelled COP and /or LNA 
probes. The probe concentrations for the Digoxigenin labelled COPs ranged from 50 to 500 
ng / ml, while those for the LNA probes were 40 nM. The ISH methodologies used are 
summarised in Table 2. Special care was taken to ensure an RNase-free environment. All 
glassware was sterilised to ensure RNase free activity. Gloves were worn at all times and 
RNase depleted water (DEPC water) was used in the preparation of solutions. 
For qRT-PCR, RNA was extracted from cell lines using Trizol (Sigma, U.K.) and RNA 
concentration and purity were measured using a NanoDrop spectrophotometer at 260 nm 
and 280 nm. RNA was reverse-transcribed to cDNA using the qScript microRNA cDNA 
Synthesis Kit (Quantabio, UK.) according to the manufacturer's instructions. The resulting 
cDNA was used to assess the expression of miR-21, while U6-snRNA and hsa-let-7a-5p were 
used as a reference RNA for normalization of miRNA expression levels. The PerfeCTa SYBR® 
Green SuperMix (Quantabio, UK.) was used together with MystiCq microRNA qRT-PCR 




































































U6-snRNA primers were U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and hsa-let-7a-
5p forward 5’-CCGAGCTGAGGTAGTAGGTTGTATA-3’ together with reverse 5′-
CGCTTCACGAATTTGCGTGTCAT-3′ for both. Thermocycling conditions were: initial 
denaturation at 95 °C for 2 mins, followed by 40 cycles of 95 °C for 5 secs, 60 °C for 15 secs, 
and terminating extension at 72 °C for 15 secs. Each run was repeated three times in 
triplicate. 
Microscopic staining patterns were assessed qualitatively concentrating on identification of 
the cellular structures stained by the ISH probes. According to a standard method the 
intensity of staining was classified as weak, moderate or strong. For the prostate tissue 
samples the proportion of tumour glands in which staining was present was qualitatively 
determined. 
The relative expression of miR-21 by qRT-PCR in the LNCaP and PC3 cell lines was 
normalized with U6 and let-7 expression using the comparative Cycle Threshold method 
[10]. The mean and standard deviation was then determined while t-Test and p values 
provided a comparator between the expression of miR-21 in the cell lines. 
Results 
COP ISH work up was undertaken using three cases each of CRC and SCC of lung together 
with two cases of IBC. The preservation of mRNA confirmed in all of the cases using the poly 
d (T) probe. The results were also used as a guide to determine the optimal Proteinase K 
pre-treatment for the cases. This was either 2 or 5 Pg / ml. 
The optimal probe concentration for miR-126 COP in the CRC and SCC of lung cases was 400 




































































was observed (Fig 1a, 1b). In the IBC cases the optimal probe concentration was 500 ng / ml. 
In these cases endothelial staining was variably demonstrated and was supplemented by 
weak to moderate staining of the tumour islands (Fig 1e). In one case epidermis was present 
and this was also weakly stained for miR-126.  
The optimal probe concentration for miR-205 COP in the CRC, SCC of lung and IBC cases was 
500 ng / ml. In two of the CRC cases miR-205 was demonstrated in the tumour and 
uninvolved glandular epithelium (Fig 1c). The staining of the former was of weak to strong 
intensity, while in the latter strong staining was noted. In the remaining CRC case general 
staining of weak to moderate intensity was observed with no discrimination between 
tumour and stromal areas. Tumour islands and individual tumour cells were moderately to 
strongly stained in two cases of SCC of lung with the miR-205 COP (Fig 1d, 1g). In the 
remaining SCC of lung case no obvious tumour cells were present and staining for miR-205 
was absent. Tumour islands in the IBC cases were stained at moderate to strong intensity. 
Epidermis, present in one case, was stained by the miR-205 COP at strong intensity.  
The comparison of miR-126 ISH using COP and LNA probes was undertaken for miR-126 
using the IBC cases. Endothelial and tumour staining was observed with both probe types in 
both cases. However, endothelial staining was more consistently demonstrated with the 
LNA probe. Staining of the tumour islands in one case with the LNA miR-126 probe was 
intense and obscured the staining of adjacent capillaries and small blood vessels (Fig 1f). In 
contrast the staining of the tumour islands in this case using COP ISH was weaker and 
endothelial staining in capillaries and small blood vessels clearly identifiable (Fig 1e). 
Epidermis, present in one case, was stained with miR-126 LNA at strong intensity and 




































































Comparative ISH for miR-205 was undertaken using the two IBC cases and one case of SCC 
of lung. In all cases equivalent staining was observed using the COP and LNA ISH 
protocols. Tumour islands and epidermis were stained, respectively, at moderate and strong 
intensity in the IBC cases. Moderate to strong staining of the tumour islands and individual 
tumour cells in the SCC of lung was observed (Fig 1g, 1h). 
A clear distinction was observed on miR-21 expression by qRT-PCR between the highly 
metastatic androgen independent PC3 and less metastatic LNCaP androgen sensitive cell 
lines. For the PC3 cells line the mean and standard deviation from the normalised 
expression levels was 13.7 and 3.6 respectively. For the LNCaP cell line the mean and 
standard deviation was 3.372 and 1.5 respectively. The t-Test value between the cell lines 
was 0.0023.  In the PC3 cells miR-21 expression was 160-fold greater than that recorded for 
the LNCaP cells (n=3; p=0.002). This differential expression was mirrored in the COP ISH 
results (Fig 1i, 1j). 
Of the 20 Gleason stage 7 cases one did not stain for mRNA using the poly d (T) probe. In the 
remaining 19 cases satisfactory staining was observed and these cases were taken forward 
for ISH using miR-21 and scrambled COP probes. The sections were pre-treated with 
Proteinase K at 5 or 10 ug / ml before hybridisation with the probes. Specific staining of the 
tumour glands at varying intensity and distribution was observed in 14 of the 19 cases, while 
in three cases non-specific staining of the tissue only was present and in the remaining two 
cases no staining was observed (Fig 1k, Table 3). No specific staining was recorded in 






































































miRNAs have been demonstrated using a variety of ISH protocols. Thompson, et al [11] 
described a method using fluorescein labelled oligonucleotide probes that was complicated 
and took three days to perform. The technique was simplified by Nuovo, [12] and a one-day 
chromogenic technique using LNA probes was described by Jørgensen, et al [9]. 
The objective of this study was to establish if COPs could be used as an alternative to LNA 
probes for ISH to demonstrate miRNAs in FFPE preparations. Three miRNA targets were 
chosen to assess if this was possible, miR-21, miR-126 and miR-205. These were chosen as 
existing LNA ISH data was available [9] and expression profiles have been established 
using qRT-PCR methods in the tissues used in the present study. 
miR-21, normally expressed in variety of haematopoietic cells, has been shown to be 
overexpressed in several tumour types and is considered to be an oncomiR [13,14]. miR-21 
is associated with prostate cancer where in vivo models have shown that it can override 
androgen dependency [15] and promote metastatic growth [16]. In a meta-analysis of 
miRNAs and prostate cancer Song, et al [17] highlighted miR-21 as being associated with 
poor recurrence free survival. Combined ISH and immunohistochemical studies [18,19] have 
demonstrated localisation of miR-21 to prostatic epithelium and matched PTEN expression. 
Present in endothelial cells miR-126 is important in the control of angiogenesis [20,21]. miR-
126 has also been shown to be associated with cancer, with the levels being decreased in 
CRC [22,23], hepatocellular carcinoma [24] and non-small cell lung cancer [25]. 
miR-205 is expressed in normal squamous epithelia and in head and neck SCC [26,27]. An 




































































cell lines [29]. Lebanony, et al [30] demonstrated miR-205 expression in SCC of lung to be 
higher than other forms of non-small cell lung cancer. Using LNA ISH Quesne, et al [31] 
reported the association of miR-205 with ductal breast carcinoma, while Wu, et al [32] 
reported suppression of cell growth and invasion by miR-205 in breast cancer. 
The results of this study provide evidence that COP ISH can be used to demonstrate miRNAs 
in FFPE cell and tissue preparations. Furthermore, in terms of the known distribution of the 
three miRNAs studied, the results are in broad agreement with reports as summarised 
above. The strong staining of miR-126 in endothelium, miR-205 in normal epidermis and SCC 
of lung was as expected [20,21,26,27,28]. The staining of the tumour islands in IBC with the 
miR-205 also matches the expression profile of this miRNA for this cancer [31,32]. The 
differential expression of miR-205 in CRC with stronger staining of the miRNA in normal 
glandular epithelium compared with that in adjacent adenocarcinoma and the weak staining 
of miR-126 in the tumour islands of IBC illustrate the finesse of the ISH procedure and how 
this can add value to understanding expression levels obtained using qRT-PCR based 
methods. 
The COP ISH method was compared with the LNA ISH procedure using probes of identical 
sequence in cases of IBC and SCC of lung. Endothelium was demonstrated more consistently 
using miR-126 LNA ISH than with COP ISH. The intensity of staining for this miRNA was 
also greater with the former probe in the tumour islands of an IBC case and in normal 
epidermis than in tissues hybridised using the COP ISH procedure. These results could be 
explained by the higher hybridisation efficiency of the LNA probe. However, the 
demonstration of miR-126 in normal epidermis was not expected with the LNA probe. 




































































The results with the miR-21 COP ISH in the PC3 and LNCaP prostate cell lines were in line 
with the expression levels obtained using qRT-PCR reflecting their respective androgen 
independent and androgen sensitive derivation. This demarcation was also observed 
between the qualitative ISH and quantitative qRT-PCR. The staining in the Gleason stage 7 
prostate biopsies confirmed an epithelial localisation for miR-21 in 74% of the 19 cases 
(Table 3) pointing to the utility of the use of COP probes for ISH.  
The ISH results in the prostate tissues showed heterogeneity in demonstration of miR-21. 
This may reflect non-uniform expression due to underlying pathophysiology or it may point 
to the effect of formalin-based fixation. miRNA has been shown to be particularly resistant 
to the degrading effects of formalin on nucleic acids [33], but this does not imply that its 
effects will be uniform. This can be influenced by fixation time and the ease by which 
formalin can penetrate to all areas of a tissue to fix them.  
From a practical view the LNA ISH protocol as described by Jørgensen, et al [9] provides 
results in an extended ‘working’ day while the COP ISH method is considerably longer. This 
difference should not be of consequence in a research environment, but could be a 
consideration in a diagnostic setting. An advantage of COP ISH is that it frees investigators 
from the need to purchase proprietary based LNA probes. COPs can also be acquired at 
reduced price and in quantities that can support their use over many more ISH runs. 
This work represents an advance in biomedical science because it demonstrates that COPs 
can be used for ISH on FFPE samples with an expectation that they will produce equivalent 
results to of LNA probes for the demonstration of miRNAs.  





































































What is known about this subject? 
The expression levels of miRNAs can be quantitatively determined using molecular methods 
such as qRT-PCR.  
In heterogenous samples the cellular localisation of differentially expressed miRNAs should 
be established using in situ hybridisation (ISH). 
Using locked nucleic acid (LNA) probes in ISH can reliably demonstrate miRNAs in formalin 
fixed paraffin embedded (FFPE) preparations. 
What this paper adds? 
ISH using conventional oligonucleotide probes (COP) is described providing equivalent 
results to the use of LNA in FFPE samples. 
qRT-PCR undertaken on prostate cancer cell lines and COP ISH gave equivalent results. 
The use of COPs for ISH provides economic savings in procurement while allowing for an 
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 Table 2: In situ hybridisation m
ethodologies 
 




Digoxigenin locked nucleic acid 





Rehydrate sections, cover w
ith Proteinase K and incubate for 30 m
ins at 37 qC, w
ash in DEPC w
ater. 
Hybridisation 
Dehydrate and air dry sections, add probe, incubate 
for 2 h at 37 qC, im
m
erse in TBS. 
Incubate w
ith pre-
hybridisation solution for 1 h 
at 37 qC.  Add equal volum
e of 
hybridisation solution, 
incubate overnight at 37 qC. 
Im
m
erse in TBS. 
Dehydrate and air dry sections. 
Denature probes, hybridise for 1 
h at 55 qC. W
ash in 5 X SSC  
reducing to 0.2 X SSC at 55 qC 





erse in TBS. 
Detection 
Add TBSBT blocking solution, incubate for 10 m
ins. 
Tip off, add anti-FITC antibody conjugated to 
As for poly d (T) probe except 
for use of anti-Digoxigenin 
As for Digoxigenin labelled 








































































































































































































Laboratories) diluted 1:100 in TBSBT and incubate 
for 30 m
ins. Rinse in TBS, w
ash in alkaline 
phosphatase substrate buffer. Cover sections w
ith 
alkaline phosphatase substrate solution, incubate in 





ater (3 / 1 VV). 
antibody conjugated to 
alkaline phosphatase 
(11093274910, Roche) diluted 
1:600 in TBSBT w
ith overnight 
incubation in the alkaline 
phosphatase substrate. 
incubation in alkaline 
phosphatase substrate for 1-2 h. 
Legend 




 Tris-HCl, 150 m
M
 sodium
 chloride, pH7.6 
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 TBSBT: TBS plus 0.1%
 Tw










 chloride hexahydrate, 100m
M
 sodium
 chloride, pH 9.0. 
Substrate solution: Ready to use N
itroblue tetrazolium
 / 5-Brom






isole and 0.2 -0.5Pm
 pore size filtered before use. 








































































































































































































Table 3 Prostate carcinoma ISH of 19 cases for miR-21 using conventional oligonucleotide 
probes 
miR-21 staining patterns Cases 
Moderate to strong staining of some glands 2 
Moderate staining of some glands 3 
Weak to moderate staining of some glands 1 
Weak staining of majority of glands 4 
Weak staining of few glands 4 
No specific staining 3 





































































Figure 1: Demonstration of miRNA by conventional oligonucleotide (COP) and locked 
nucleic acid (LNA) probes. 
Legends 
a) CRC, miR-126, COP probe, (x100 magnification). b) SCC of lung miR-126, COP probe, (x400 
magnification). Note: strong staining of endothelium of capillaries and blood vessels. 
c) CRC, miR-205, COP probe, (x 100 magnification). Note: strong staining of normal epithelial 
glands (left) and moderate staining of adenocarcinoma (right). d) SCC of lung, miR-205, COP 
probe, (x 400 magnification). Note: strong staining of tumour islands. 
IBC e) miR-126 COP probe, (x100 magnification). Note: Moderate staining of tumour islands 
(right) together with strong staining of blood vessels (arrows). f) miR-126 LNA probe, 
(x100 magnification). Note: strong staining of tumour islands (right). 
SCC of lung: g) miR-205 COP probe, (x100 magnification). h) miR-205 LNA probe, (x100. 
magnification) Note: strong staining of tumour islands with both probes 
Prostate carcinoma miR-21COP ISH, (x400 magnification): i) PC3 cell block section. Note: 
strong staining of several cells j) LNCaP cell block section. Note absence of specific staining. 





































































Figure 1: Demonstration of miRNA by conventional oligonucleotide (COP) and locked 
nucleic acid (LNA) probes. 
 a)  b) 
a) CRC, miR-126, COP probe, (x100 magnification). b) SCC of lung miR-126, COP probe, (x400 
magnification). Note: strong staining of endothelium of capillaries and blood vessels. 
 c)  d) 
c) CRC, miR-205, COP probe, (x 100 magnification). Note: strong staining of normal epithelial 
glands (left) and moderate staining of adenocarcinoma (right). d) SCC of lung, miR-205, COP 




































































 e)  f) 
IBC e) miR-126 COP probe, (x100 magnification). Note: Moderate staining of tumour islands 
(right) together with strong staining of blood vessels (arrows). f) miR-126 LNA probe, 
(x100 magnification). Note: strong staining of tumour islands (right). 
 g)  h) 
SCC of lung: g) miR-205 COP probe, (x100 magnification). h) miR-205 LNA probe, (x100. 




































































 i)  j) 
 k) 
Prostate carcinoma miR-21COP ISH, (x400 magnification): i) PC3 cell block section. Note: 
strong staining of several cells j) LNCaP cell block section. Note absence of specific staining. 


















































































































Table 2: In situ hybridisation m
ethodologies 
 




Digoxigenin locked nucleic acid 





Rehydrate sections, cover w
ith Proteinase K and incubate for 30 m
ins at 37 qC, w
ash in DEPC w
ater. 
Hybridisation 
Dehydrate and air dry sections, add probe, incubate 
for 2 h at 37 qC, im
m
erse in TBS. 
Incubate w
ith pre-
hybridisation solution for 1 h 
at 37 qC.  Add equal volum
e of 
hybridisation solution, 
incubate overnight at 37 qC. 
Im
m
erse in TBS. 
Dehydrate and air dry sections. 
Denature probes, hybridise for 1 
h at 55 qC. W
ash in 5 X SSC  
reducing to 0.2 X SSC at 55 qC 





erse in TBS. 
Detection 
Add TBSBT blocking solution, incubate for 10 m
ins. 
Tip off, add anti-FITC antibody conjugated to 
As for poly d (T) probe except 
for use of anti-Digoxigenin 
As for Digoxigenin labelled 




Laboratories) diluted 1:100 in TBSBT and incubate 
for 30 m
ins. Rinse in TBS, w
ash in alkaline 
phosphatase substrate buffer. Cover sections w
ith 
alkaline phosphatase substrate solution, incubate in 





ater (3 / 1 VV). 
antibody conjugated to 
alkaline phosphatase 
(11093274910, Roche) diluted 
1:600 in TBSBT w
ith overnight 
incubation in the alkaline 
phosphatase substrate. 
incubation in alkaline 
phosphatase substrate for 1-2 h. 
Legend 




 Tris-HCl, 150 m
M
 sodium
 chloride, pH7.6 
Pre-hybridisation solution: 600 m
M
 sodium
 chloride,1 x PE buffer w
ithout SDS and bovine serum
 album
in, 10%









Hybridisation solution: As for pre-hybridisation solution w
ith addition of Digoxigenin labelled conventional oligonucleotide 
TBSBT: TBS plus 0.1%
 Tw










 chloride hexahydrate, 100m
M
 sodium
 chloride, pH 9.0. 
Substrate solution: Ready to use N
itroblue tetrazolium
 / 5-Brom






isole and 0.2 -0.5Pm
 pore size filtered before use. 
SSC: Standard Saline Citrate buffer, pH 7.0. 
 
Table 3 Prostate carcinoma ISH of 19 cases for miR-21 using conventional oligonucleotide 
probes 
miR-21 staining patterns Cases 
Moderate to strong staining of some glands 2 
Moderate staining of some glands 3 
Weak to moderate staining of some glands 1 
Weak staining of majority of glands 4 
Weak staining of few glands 4 
No specific staining 3 
Unstained  2 
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